Bioteque Corporation 邦特生物科技股份有限公司 [time:2026Q1] 法說會簡報

Company Overview

• Company Name: Bioteque Corporation (邦特生物科技股份有限公司)
• Presenter: 黃繹中 (Huang Yi-Chung)
• Date: 2026/05/18
• Slogan: Improving lives
• Mission: 行銷全球專業醫材製造商 (Marketing globally as a professional medical device manufacturer).
• Leadership Position: 台灣醫療器材專業領導廠商 (Taiwan's leading professional medical device manufacturer).
• Founding Year: 1991年
• Listing Status: 2002年於櫃檯買賣中心上櫃交易 (Listed on the over-the-counter market in 2002).
• Headquarters/Main Factory Location: 宜蘭的龍德工業區 (Longde Industrial Park, Yilan).
• Employee Count: 430人
• Certifications:
  • 品質系統 (Quality System): QMS (台灣), ISO-13485
  • 主要產品取得CE認證 (Main products are CE certified)
  • 美國FDA510(k) (US FDA 510(k))
• Honors:
  • 榮獲2013年國家品質獎 (National Quality Award in 2013)
  • 2019年傑出生技產業獎 (Outstanding Biotech Industry Award in 2019)
• Factories:
  • 宜蘭廠 (Yilan Factory): 佔地約14,820m²
  • 宜科新廠 (Yilan Science Park New Factory): 佔地約32,000m²
  • 菲律賓子公司 (Philippines Subsidiary):
    • Name: BMPI, Bioteq Medical Phil. Inc.
    • Ownership: 邦特生技100%持有 (100% owned by Bioteque Corporation).
    • Established: 2013年
    • Operational Start: 2014年起
    • Location: 菲律賓巴丹省的HEIP的PEZA工業區 (HEIP's PEZA Industrial Zone in Bataan Province, Philippines).
    • Employee Count: 400餘員 (Over 400 employees).
    • Area: 佔地約34,288m²

Financial Highlights

折舊費用分析表 (Depreciation Expense Analysis Table)

單位: 仟元 (NT$ thousands)

合併營收收入比較 (Consolidated Revenue Comparison)

單位: 千元 (NT$ thousands)

合併公司基本EPS比較 (Consolidated Basic EPS Comparison)

單位: 元 (NT$)

合併公司毛利率比較 (Consolidated Gross Margin Comparison)

單位: %

匯率風險變動對公司之影響 (Impact of Exchange Rate Fluctuations on the Company)

單位: 千元 (NT$ thousands)

Business Segments

• Specialization: 生產與銷售 (Production and sales) for:
  • 血液透析 (Hemodialysis)
  • 介入放射科 (Interventional Radiology)
  • 泌尿科 (Urology)
  • 心血管科 (Cardiovascular)
  • 加護病房 (Intensive Care Unit)
  • 所需之醫療耗材 (Required medical consumables).

Products & Technologies

• Products:
  • 血液透析 (Hemodialysis): 血液迴路管 (Blood tubing sets), 非DEHP迴路管 (Non-DEHP tubing sets), 動靜脈廔管穿刺針 (AV fistula needles).
  • 介入放射科 (Interventional Radiology): 體內導管 (Intracorporeal catheters), 血管導管 (Vascular Catheters), 周邊產品 (Peripheral products).
  • 泌尿科 (Urology): 體內導管 (Intracorporeal catheters), 周邊產品 (Peripheral products).
  • 心血管科 (Cardiovascular): 體內導管 (Intracorporeal catheters), 周邊產品 (Peripheral products).
  • 輸液軟袋 (Infusion soft bags), 藥用軟袋 (Medical soft bags).
  • 外科管 (Surgical Tubes).
  • 關鍵零組件 (Key Components).
  • 附件 (Accessories).
• Core Capabilities:
  • 高分子押出 (Polymer extrusion)
  • 射出 (Injection molding)
  • 焊鎔 (Welding/Fusion)
  • 特殊塑型 (Special molding)
  • 模具開發 (Mold development)
  • 高周波熔接 (High-frequency welding)
  • 自動化 (Automation)
  • 研發設計 (R&D design)
  • 品質確保 (Quality assurance)
• Technology Platforms / Facilities:
  • 100,000 級無塵室 (Class 100,000 cleanroom)
• Equipment:
  • 日製電動高分子射出機 (Japanese-made electric polymer injection molding machines)
  • 押出機 (Extrusion machines)
  • 滅菌鍋 (Sterilizers)
  • 自動化組裝機 (Automated assembly machines)

Clients & Markets

區域別營業收入比重比較 (Revenue Proportion Comparison by Region)

單位: 千元 (NT$ thousands)

Outlook & Strategy

2026年營業策略規劃 (2026 Business Strategy Planning)

• 一、針對低毛利產品(血液迴路管)之因應策略 (Strategies for low-margin products (blood tubing sets))
  • 面對挑戰 (Challenges): 美伊戰爭造成原料上漲 (US-Iran war caused raw material price increase).
  • 應對措施 (Countermeasures):
    1. 與內銷客戶協調價格調整 (Coordinate price adjustments with domestic customers).
    2. 與菲律賓經銷商加強產品銷售,協助取得公立醫院年度標案 (Strengthen product sales with Philippine distributors, assist in securing annual tenders from public hospitals).
    3. 持續提升生產效率,降低生產成本 (Continuously improve production efficiency, reduce production costs).
• 二、宜科新廠營運進展 (Yilan Science Park New Factory operational progress)
  • 目前狀況 (Current Status):
    1. 部分客戶開始移廠生產,提高工廠利用率 (Some customers have started transferring production to the new factory, increasing factory utilization).
    2. 準備將新購置軟袋機建置到宜科廠 (Preparing to install newly purchased soft bag machines in the Yilan Science Park factory).
    3. 預計2027第一季,第一台軟袋機抵達宜科廠 (First soft bag machine expected to arrive at Yilan Science Park factory in Q1 2027).
• 三、因應地緣政治考量將勞力密集的產品持續規劃移往菲律賓廠 (Due to geopolitical considerations, continuously planning to transfer labor-intensive products to the Philippines factory)
  • 1. 準備相關產品轉移驗證工作 (Preparing for related product transfer validation work).
  • 2. 與客戶持續溝通,做好備援生產準備 (Continuously communicate with customers and prepare for backup production).

Additional Data

產品別收入兩期比較 (Product Revenue Two-Period Comparison)

單位: 仟元 (NT$ thousands)